Elevated plasma eda fibronectin in primary myelofibrosis is determined by high allele burden of jak2v617f mutation and strongly predicts splenomegaly progression

HIGHLIGHTS

• who: Alessandro Malara from the National Institute of Health (ISS), Italy Boston University, United States have published the research work: Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression, in the Journal: (JOURNAL)
• what: The aim of this study was to define the plasma levels of EDA-FN in a large, well-characterized, cohort of PMF patients. To explain the association of EDA-FN levels with splenomegaly and spleen size progression in PMF the authors focused on its well-known role in tumor . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.